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o Large quantities of whey are generated annually by the
cheesemaking industries and concerns about the
environment have made them seek new alternatives for
their effluents;
o Whey proteins and peptides are one of these byproducts
which is recognized for reducing risk factors of numerous
diseases, including hypertension;
o Despite the need of better use of this agroindustrial residue
and the high prevalence of hypertension worldwide, whey
based-products that are able to modulate blood pressure
are very scarce in food and nutraceutical markets,
emphasizing the need of more research regarding this
theme. The development of new products requires several
stages in which scaling-up the production is comprised.
o The present study proposed to optimize the process of
development of a new antihypertensive whey hydrolysate in
semi-pilot scale, assessing the influence of drying
technologies and enzyme inactivation conditions on its
biofunctionality.
The present study revealed that the spray-dry technology was effective in
maintaining the antihypertensive potential of the hydrolysate, besides being more
affordable to food industries. Moreover, the enzyme inactivation seemed to be an
important step in the process for the obtainment of a biofunctional ingredient,
since thermally inactivated samples achieved vascular relaxations above 70%. In
this manner, thermic inactivation of the enzyme and spray-drying the hydrolyzed
solution were the best alternatives for the development of antihypertensive whey
hydrolysate in a semi-pilot scale.
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Figure 1: Design of an industrial plant for whey protein hydrolysate production.
Figure 2: Peptide profiles of whey hydrolysates. (A) chemically inactivated and freeze-dried;
(B) chemically inactivated and spray-dried; (C) thermally inactivated and freeze-dried; (D)
thermally inactivated and spray-dried. Upper windows show β-lactoglobulin.
Figure 3: Vascular
relaxations induced by
cumulative concentration
of 1, 3, 5, 10 mg.mL-1 of
whey hydrolysates.
Letters a and b indicate
significant difference
(p<0.05).
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